GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adial Pharmaceuticals Inc (NAS:ADIL) » Definitions » Cash, Cash Equivalents, Marketable Securities

Adial Pharmaceuticals (Adial Pharmaceuticals) Cash, Cash Equivalents, Marketable Securities : $2.83 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Adial Pharmaceuticals Cash, Cash Equivalents, Marketable Securities?

Adial Pharmaceuticals's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($1.22 Mil) to Sep. 2023 ($0.32 Mil) but then increased from Sep. 2023 ($0.32 Mil) to Dec. 2023 ($2.83 Mil).

Adial Pharmaceuticals's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($6.06 Mil) to Dec. 2022 ($4.00 Mil) and declined from Dec. 2022 ($4.00 Mil) to Dec. 2023 ($2.83 Mil).


Adial Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Adial Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adial Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Chart

Adial Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only 6.78 4.40 6.06 4.00 2.83

Adial Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 2.31 1.22 0.32 2.83

Adial Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Adial Pharmaceuticals  (NAS:ADIL) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Adial Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Adial Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Adial Pharmaceuticals (Adial Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adial Pharmaceuticals Inc (NAS:ADIL) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
1180 Seminole Trail, Suite 495, Charlottesville, VA, USA, 22901
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.
Executives
Kevin Schuyler director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Stilley William B. Iii director, 10 percent owner, officer: Chief Executive Officer 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Newman James W. Jr. director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Bankole A. Johnson director, 10 percent owner 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Jack W Reich director C/O COLLATERAL THERAPEUTICS, 11622 EL CAMINO REAL, SAN DIEGO CA 92130
Tony Goodman director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
J. Kermit Anderson director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Joseph Truluck officer: COO and CFO 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Robertson H. Gilliland director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
En Fidecomiso De Mi Vida 11/23/2010 Trust 10 percent owner 11024 GAITHER FARM ROAD, ELLICOTT CITY MD 21042

Adial Pharmaceuticals (Adial Pharmaceuticals) Headlines

From GuruFocus